In April 2026, the FDA approved brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma (MCL), offering the potential for long-term remissions, according to Lore Gruenbaum. The decision was based on results from the ZUMA-2 trial, which showed high response rates across patient groups. In earlier-line patients, the overall response rate was 91% with 79% achieving complete remission, while later-line patients had an 87% response rate and 62% complete remission. Median duration of response has not yet been reached.
While the therapy is highly effective, access remains a challenge due to eligibility, geographic, and financial barriers. The approval emphasizes the importance of personalized care, taking patient comorbidities and circumstances into account.
Future research is focusing on the best sequencing of therapies, exploring post-CAR T options like bispecific antibodies, and expanding access to ensure more patients can benefit from these advanced cellular treatments.